Breaking Finance News

A statement released earlier today by RBC Capital about Tesaro (NASDAQ:TSRO) bumps the target price to $128.00

RBC Capital bumped up the target of Tesaro (NASDAQ:TSRO) to $128.00 stating a potential upside of 0.29%.

On 9/06/2016, Lake Street released a statement for Tesaro (NASDAQ:TSRO) bumped up the target price from $0.00 to $114.00 that suggested an upside of 0.31%.

Boasting a price of $99.26, Tesaro (NASDAQ:TSRO) traded -0.63% lower on the day. With the last stock price close up 43.94% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Tesaro has recorded a 50-day average of $96.42 and a two hundred day average of $68.96. Volume of trade was up over the average, with 1,364,793 shares of TSRO changing hands over the typical 1,009,710

Performance Chart

Tesaro (NASDAQ:TSRO)

With a total market value of $0, Tesaro has with a one year low of $29.51 and a 52 week high of $110.48 .

In addition to RBC Capital reporting its stock price target, a total of 10 brokerages have issued a research note on the company. The average stock price target is $89.00 with 8 brokerages rating the stock a strong buy, 4 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Tesaro (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *